 "Rewind 2018: Tough regulatory regime for pharmaceutical industry")
It was a rough year for the pharmaceutical industry in more ways than one. Apart from the ban on over 300 fixed-dose combinations, and the rise in prices of bulk drugs because of manufacturing slowdown in China, there were signs of volatility in domestic sales because of the base effect of the goods and services tax (GST) implemented in 2017.
The falling rupee, however, helped firms offset the impact of input cost hikes in the second quarter. Exports were buoyant, hitting $11 billion in the April-October period.
It is expected to cross the $17.27-billion mark achieved in 2017-18. Though investment on research and development has more than doubled over the past five years — from $700 million per annum to $1.6 billion a year — there are signs of slowdown, as companies are exercising caution while choosing molecules to invest in.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%